The first drug to improve cardiac function in cardiac amyloidosis, an incurable and often fatal disease, has been successfully tested by scientists at the Puerta de Hierro University Hospital. The results of the study are published in the journal NEJM.
In cardiac amyloidosis, filaments of amyloid proteins accumulate in the heart muscle, leading to thickening of the heart walls, increased stiffness, and heart failure. The prognosis of the disease is poor, and without appropriate therapy, patients die on average after three years.
The initial results of the study, which included 40 patients from France, the Netherlands, Germany and Spain, indicate that the new antibody-based drug is safe and likely to reduce the amount of amyloid protein in the heart. Patients were administered the drug gradually intravenously.
The Swiss company Neurimmune has created a new drug, which is an antibody that binds to the amyloid protein transthyretin and prevents its accumulation in the heart. To obtain this antibody, immune B cells extracted from healthy elderly people were used. Gazeta.ru .
Read the Latest World News Today on The Eastern Herald.
